About Matritech
Matritech is a Healthcare company based in Newton (United States) founded in 1996, and was acquired by Abbott in August 2007. Protein-based point-of-care tests for biomarker detection are developed. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Bladder Cancer. Its competitors include Alamar Biosciences, Sequenta and Crescendo Bioscience; 3 of its 3 listed competitors have raised funding.
Company details
Matritech developed protein-based point-of-care diagnostic tests. It used proteomics to identify clinically relevant disease-related biomarkers. Its flagship product NMP22 BladderChek is a urine-based lateral flow test for the early detection of bladder cancer. The test requires four drops of urine to run and has a turnaround time of 30 minutes. The test is CE marked and CLIA-waived. In Dec 2007, Inverness (now known as Alere) acquired the company for 36M, with an additional 2M in milestone based payments.
- Headquarters Newton, United States
- Stage Acquired
- SectorsHealthcare
- Website matritech.com
- Acquired by Abbott (Aug 2007)
- Latest Funding Round$4.36M (USD), Post-IPO
Jan 2007
- InvestorsTekla Capital Management
& 1 more
- Acquired byAbbott
(Aug 2007)
Funding Insights of Matritech
- Total Rounds 6
- Last Round Post-IPO — $4.36M
- First Round $4M
(Apr 1999)
- Investors Count 1
All 6 funding rounds of Matritech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2007 | $4.36M | Post-IPO | – | – | |
| Jan 2006 | $7M | Post-IPO | – | – | |
| Mar 2004 | $6.56M | Post-IPO | – | – | – |
| Mar 2002 | $4.3M | Post-IPO | – | – | – |
| Aug 2000 | $30M | Post-IPO | – | – | – |
| Apr 1999 | $4M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Matritech
Matritech has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Tekla Capital Management and Abbott Global Point of Care.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment advisory services are provided to financial clients. | 1986 | teklacap.com | Boston, United States | |
Rapid diagnostics products and solutions for point-of-care testing are provided. | 1900 | globalpointofcare.abbott | Waukegan, United States |
Investor details for Matritech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Matritech
4 dated milestones of Matritech across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Matritech is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Post-IPO, of $4.4M.
- Exit Acquired by Abbott.
Competitors of Matritech
Matritech has 3 listed competitors in our database, 3 of them funded. They include Alamar Biosciences, Sequenta and Crescendo Bioscience.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alamarbio.com | 2018 | Fremont, United States | $180M | Ultra-high sensitivity protein analysis solutions are provided across multiplex levels. | ||
| sequenta.com | 2008 | San Francisco, United States | $43.46M | 58 | Immuno-sequencing products are developed for disease diagnostics and treatment. | |
| crescendobio.com | 2002 | San Francisco, United States | $122.05M | 128 | Molecular tests for autoimmune and inflammatory diseases are provided. |
Detailed competitors of Matritech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Matritech (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Matritech
Matritech was founded in 1996 and raised its 1st funding round 3 years after it was founded.
Matritech is headquartered in Newton, United States. It is registered at Newton, Massachusetts, United States.
Matritech developed protein-based point-of-care diagnostic tests. It used proteomics to identify clinically relevant disease-related biomarkers. Its flagship product NMP22 BladderChek is a urine-based lateral flow test for the early detection of bladder cancer. The test requires four drops of urine to run and has a turnaround time of 30 minutes. The test is CE marked and CLIA-waived. In Dec 2007, Inverness (now known as Alere) acquired the company for 36M, with an additional 2M in milestone based payments.
Matritech's top competitors include Alamar Biosciences, Sequenta and Crescendo Bioscience.
Matritech has 2 investors. Key investors include Tekla Capital Management, and Abbott Global Point of Care.
Yes. Matritech was acquired by Abbott in August 2007.